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Two four-treatment crossover studies were performed using t2 adult male volunteers in each with 
seven different commercially available prednisolone tablets. Plasma samples were assayed for 
prednisolone by a radioimmunoassay method. Statistical analyses of the data, by analysis of 
variance for crossover design (ANO VA ), showed no significant differences among the treatment 
averages at any of the sampling times except at 0.25 and 4 hr in one of the studies. There were also 
no significant differences among the treatment averages for peak plasma level, time of peak 
plasma level, area 0-12hr, area 0-24 hr, and the half-life of elimination of prednisolone. We 
conclude that the average plasma concentrations of prednisolone are superimposable in a 
statistical sense and that the tablets tested are bioequivalent. Results o[ dissolution studies of six 
tablets of each of the seven lots of prednisolone tablets, using deaerated water in the spin filter 
apparatus, are presented. 
KEY WORDS: prednisolone bioavaitability; prednisolone radioimmunoassay; prednisotone 
plasma concentrations; elimination half-life of prednisolone; in vitro rate of dissolution of 
prednisotone from tablets. 
I N T R O D U C T I O N  
Prednisolone, 1 lfl, 17,21-trihydroxypregna- 1,4-dien-3,20-dione, is a 
potent  corticosteroid that is offered for the palliative treatment of 
rheumatoid arthritis and various other diseases. Partly because of the low 
solubility of the drug (1), the Ad Hoc Committee on Drug Product Selection 
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of the Academy of General Practice of Pharmacy included prednisolone in a 
list of drugs susceptible to bioavailability problems (2). Since then very few 
studies have appeared in the literature reporting the biological availability of 
prednisolone; most of these were recently reviewed in a monograph on 
prednisolone (3), The reviewers noted that with the exception of one study 
(4) all studies suffer from a number of serious experimental defects. The 
investigators, in these reports either have used high doses of prednisolone 
and failed to follow plasma levels of the drug for more than two half-lives 
with an insensitive colorimetric assay method (5), orhave used a nonspecific 
assay and also failed to use the recommended crossover experimental design 
(6), or have studied sustained release of enteric-coated preparations (7-10). 
In view of the limited information on the in vivo availability of the corticos- 
teroid following the administration of single, low doses of prednisolone in 
the form of compressed tablets, the studies to be reported were done. This 
article reports the results of two four-treatment crossover studies utilizing 
seven different, commercially available tablets of prednisolone. 
EXPERIMENTAL 
Test Products 
The prednisolone tablets studied were obtained from the open market 
by the Food and Drug Administration, who reported to the authors that the 
tablets had the following average percentage of declared potency (SD in 
parentheses): Mc, 98.6 (3.12); St, 103.2 (2.33); Re, 98.3 (2.51); U, 98.9 
(1.21); R, 105.7 (3.91); ST, 99.0 (3.00); O, 94.3 (2.50). The code letter(s) 
are the first one or two letters of the names of the manufacturers, and lot 
numbers are given in the footnote to Table I. 
In Vitro Studies 
The spin filter apparatus of Shah et al. (12) was used to perform in vitro 
dissolution rate studies. All the studies were performed at 37~ using 1 liter 
of deaerated water as the dissolution medium. The dissolution studies on the 
same tablets are being repeated in 0.1 N hydrochloric acid using gold- 
plated equipment, but these results will be reported in a separate communi- 
cation. The stirrer speed was maintained at 400 rpm for a period of 30 min 
and then it was changed to 800 rpm until a constant absorbance reading was 
attained. The constant absorbance value could be interpreted as the percen- 
tage of label dissolved in infinite time. Since ultraviolet-absorbing material 
in the tablet, other than prednisolone, may contribute to the percentage of 
labeled amount of prednisolone dissolved and/or the prednisolone in the 
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tablet may not all be released in a water system, the data are presented as 
"mean percentage of infinity dissolved," which is defined as the "mean 
percentage of label dissolved to an arbitrary time t divided by the mean 
percentage of label dissolved in infinite time." 
Subjec~ 
In each study, 12 adult male volunteers with no known disease, who 
weighed between 54 and 95 kg and were between 21 and 33 years of age 
were selected. Six of the t2 subjects were common to both studies. The 
subjects had good venous systems in their arms to facilitate blood sampling. 
Before each subject could be included in the study, a complete physical and 
routine blood analysis and urinalysis were carried out. As a screening 
procedure, values for the following tests were required to be in the normal 
range: chloride, COz, potassium, sodium, BUN, glucose, total protein, 
albumin, calcium phosphorus, cholesterol, uric acid, creathfine, total biliru- 
bin, alkaline phosphatase, LDH, SGOT, white cell count, hematocrit, 
hemoglobin, red cell count, and plasma 17-OHCS. Informed consent was 
obtained from all subjects. 
A recent drug history was taken for each prospective subject. All 
subjects participating in the studies received no barbiturates or other 
enzyme-inducing agents for a period of 30 days preceding initiation of the 
studies, and none concurrent with them. They received no other medication 
or alcoholic beverages for a period of 7 days before initiation of the studies, 
and none during the study periods. After screening and acceptance for the 
studies, the subjects were assigned numbers and their body weight, age, 
height, race, and body build were recorded. 4 
Treatment Schedule and Doses 
The subjects started fasting at 10 P.M. the night before administration 
of prednisolone. At 11 P.M. that night, each subject took orally 1.0 mg 
dexamethasone (as two tablets of Decadron, 0.5 rag) to suppress endogen- 
ous cortisol secretion. Suppression of endogenous corfisol was necessary 
because cortisol cross-reacts with the prednisolone antiserum used in the 
radioimmunoassay. Dexamethasone does not cross-react with the pre- 
dnisolone antiserum. 
Within 1 hr after arising, on the first day of the studies, each subject 
drank 240 ml of water. At time zero, the subjects ingested 10 mg of 
prednisolone with 180 ml of water. The tablets were swallowed whole and 
not fractured or chewed before being swallowed. No food or beverages were 
4The vital statistics of the subjects and all plasma concentrations measured in the two studies 
have been forwarded to the editor of this Journal to be placed in a repository. 
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Table I. Treatment Schedule 
Time periods 
Study Subjec t s  Group Week I Week II Week III Week IV 
I, 2, 3 1 Mc a St U Re 
4, 5, 6 2 St b Re Mc U 
7, 8, 9 3 Re c U St Mc 
10, 11, 12 4 U a Mc Re St 
1, 2, 3 1 R" ST O U 
4,5,6 2 ST I U R O 
7, 8, 9 3 U a O ST R 
10, 11, 12 4 O 8 R U ST 
aMc = C.T. prednisolone, 5 mg (McKesson, lot 3J215). 
bSt = C.T. prednisolone, 5 mg (Stanley, lot 108-303). 
c Re - C.T. prednisolone, 5 mg (Rexall, lot C41913). 
aU = Delta-Cortef, 5 mg (Upjohn, lot 945CB). 
eR=C.T. r prednisolone, 5 mg (Rondex, lot 37111). 
ST= C.T. prednisolone, 2.5 mg (Stanley, lot 63402). 
sO = C.T. prednisolone, 5 mg (Ormont, lot 151-6020). 
permit ted until 4 hr after dosing with prednisolone. From 4 hr after dosing 
with prednisolone,  food and beverages were allowed ad  l i b i tum.  Eight hours 
after the administrat ion of prednisolone, the subjects were given another  
0.5 mg tablet  of dexamethasone  to continue the suppression of hydroc-  
rotisone. A washout  period of 1 week was allowed between treatments ,  a 
period of 2 months  separated the two studies. The  t rea tment  schedules that  
were used in the two studies are shown in Table  I. 
Blood Sampling 
Fifty milliliters of blood was taken f rom the forearm vein just prior to 
dosing with prednisolone (time zero). A dilution of the 0-hr plasma was used 
in the construction of the calibration plot for the prednisolone radioim- 
munoassay.  Subsequently,  10 ml of whole blood was drawn at 0.25, 0.5, 1, 2, 
3, 4, 6, 8, 12, and 24 hr after dosing with prednisolone. Each blood sample 
was centrifuged shortly after collection; the plasma was quick-frozen and 
kept  in the frozen state ( - 2 0 ~  until just prior to assay. 
Assay Method  
Plasma samples obtained in Prednisolone Study No. 2 5 were analyzed 
by using the following procedure,  using antiserum supplied by Dr.  J. C. K. 
5Prednisolone Study No. I was that reported by Sullivan et al. (4). 
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Loo. The samples were diluted so that 1 ml of the diluted plasma contained 
between 0.4 and 10 ng of drug. Usually unknown plasma samples were 
diluted 1 : 50 (same as in preparation of standard curve), but on reassay some 
had to be diluted 1 : 10 to get the concentration in range of the standard 
curve. One milliliter of diluted 0-hr plasma was spiked with 0, 0.4, 0.8, 2, 4, 
6, and 10 ng of cold prednisolone for the binding curve. One milliliter of the 
diluted spiked plasma was extracted with 7 ml of dichloromethane 
for 5 min on a mechanical shaker. The sample was centrifuged and the 
aqueous phase was aspirated. A 5-ml aliquot of the organic phase was 
transferred to a disposable culture tube and evaporated to dryness under a 
stream of nitrogen. To the dried tube was added 50 tzl of absolute ethanol 
(wash sides), followed by 10 Iz I of [3H]prednisolone. One milliliter of saline 
phosphate buffer was then added (wash sides) followed by 10 Iz I of a solution 
of the antiserum of Loo. The mixture was vortexed and incubated in a 37~ 
water bath for 15 rain. At the end of the incubation time, the sample was 
placed in an ice bath and 0.5 ml of cold dextran-coated charcoal (5% 
charcoal, 0.5% dextran TT0) was added. The sample was allowed contact 
with the charcoal suspension for exactly 10 rain and then was centrifuged at 
0~ and 2000 rpm for 15 rain. The supernatant was quickly decanted into a 
scintillation vial containing 10 ml of Unogel and counted for 10 rain. 
The method of Sullivan et aL (4) was used to assay all samples obtained 
in Prednisolone Study No. 3, using antiserum of W. A. Colburn. Plasma 
samples were diluted to an appropriate degree so that 1 ml of diluted plasma 
contained 2-20 ng of drug. Usually unknown plasma samples were diluted 
1 : 25 (same as in preparation of the standard curve), but on reassay some 
had to be diluted 1 : 10 to get the concentration in the range of the standard 
curve. The standard curve was constructed from diluted (1 : 25) 0-hr plasma 
that was spiked with 0, 2, 4, 6, 10, and 20 ng of unlabeled prednisolone. 
All plasma concentrations of prednisolone were obtained by inverse 
estimation using the parameters of the least-squares line drawn through a 
logistic-logarithmic plot as indicated in 
r B(X) .  "~ rB(X) 1O01 ln C +  (1) 
where B(0) represents the percent-bound value when there was no pred- 
nisolone added to plasma, B(X)  represents the percent bound in the 
presence of prednisolone, S is the slope of the line, C is the concentration of 
prednisolone (ng/ml), and In O is the intercept of the regression line fitted to 
the data. Figure 1 represents the calibration curve for Prednisolone Study 
No. 2. The authors have evidence which clearly shows that this method of 
























26Z Tembo, Haibnark, Sakmar, Kachmanu, Welder,  and Wagney 
i l I I i , I  I I  J, , 
2 3 4 5 6 7 8 9 1 0  20 30 
C " C o n c e n t r a t i o n  os  p r e d n t s o l o n e  ( u g / m ~ )  o n  a l o s a r t t h m l r  s c a l e  
Wig. 1. Calibration data for prednisolone radioimmunoassay obtained by 
spiking diluted 0-hr plasma of the 12 subjects in Prednisolone Study No. 2. 
Circles represent e nr~ values, where l ~  represents the average natural 
logarithms of the function shown on the ordinate scale for the 12 subjects. The 
bars mark off the range of values for the 12 subjects. The regression line has 
the equation l ~ y  = 0.8853 In C +0.4209 and is based on 72 points. (See text 
for meaning of y.) 
because it provides less bias in the calculated prednisolone concentrations. 
The authors would like to caution other investigators who work with 
radioimmunoassays that just because a logistic-logarithmic calibration plot 
works best for estimating plasma prednisolone levels, no inference is 
intended as to the superiority of this plot over other methods of calculating 
plasma levels of other compounds. For instance, the authors have evidence 
which indicates that a logistic-logarithmic plot is quite inadequate for 
9 Bioavailabillty of Prednisoione Tablets 263 
estimating plasma levels of either prednisone or digoxin. A detailed analysis 
of radioimmunoassay data for prednisolone, prednisone, and digoxin is 
given by two of the authors elsewhere (11). 
RESULTS A N D  DISCUSSION 
In Vitro Studies 
Figure 2 shows the in vitro dissolution data obtained in the spin filter 
apparatus (12) for the seven tablets tested in vivo. Each point on each curve 
represents an average of six separate tablet determinations. There were 
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Fig.  2.  Dissolution data for the s e v e n  different 
tablets used in Prednisolone Studies No. 2 and 3 
in the spin filter apparatus of Shah et al. (12). See  
footnotes to Table ! for key to different tablets. 
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interesting to note that the 2.5 mg and 5.0 mg tablets (ST and St, respec- 
tively) of the same manufacturer released the drug at markedly different 
rates. The 2.5 mg tablet dissolved more rapidly and displayed a hyperbolic 
type of release curve, while the 5.0 mg tablet dissolved more slowly and 
displayed a sigmoid type of curve. All tablets were found to be equivalent 
with respect to availability in normal humans; therefore, for the tablets 
tested, absorption of prednisolone does not appear to be dissolution-rate 
controlled. All tablets apparently released prednisolone at an in vivo rate 
that was rapid enough so that this release did not rate-limit absorption in 
man. 
Assay Error 
in Prednisolone Study No. 2 antiserum of J. C. K. Loo was utilized and 
the standard curve (Fig. 1) is based on 72 points (the 12 subjects' 0-hr plasma 
spiked at 0.4, 0.8, 2, 4, 6, and 10 ng prednisolone per milliliter of plasma). 
The regression equation was 
n ~ y =  0.8853 In C+0.4209 (2) 
The concentrations of prednisolone in "unknown" plasmas were estimated 
by means of the rearranged form of equation 2, namely, 
d" = e ('" y-~176176 (3) 
where Iny is given by the middle portion of equation 1. 
The coefficients of variation calculated from the inversely estimated 
A 
concentrations (C), using the 12 Iny values at each concentration, were 
17.9%, 11.8%, 13.1%, 14.6%, 14.0%, and 20.3% for the known standard 
concentrations (C~) of 0.4, 0.8, 2, 4, 6, and 10 ng/ml, respectively. So-called 
A 
bias values may be calculated from the mean estimated concentrations (Cm) 
using 
1 bias value = I . ~ J  x 100 (4) 
The observed bias values were 1.3%, -3.6%, 6.5%, 7.3%, 0.3%, and 
-2 .1%,  respectively, for the concentrations in the same order. 
In Prednisolone Study No. 3, antiserum of W. A. Colburn was utilized 
and a similar standard curve to that shown in Fig. 1 was obtained. The 
standard curve for this study was based on spiking the 0-hr plasmas of 
subjects 1--6 at 2, 4, 6, 10, and 20 ng prednisolone/ml plasma. Thus the 
standard curve was based on 30 points. This was done since in Prednisolone 
Study No. 2 the logistic-logarithmic equation based on the data from 
subjects 1-6 was essentially identical to that based on subjects 1-12. 
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Because the antiserum of W. A. Colburn was less sensitive than that of J. C. 
K. Loo, the logistic-logarithmic equation was different and is shown as 
= 1.0593 In C -  1.1214 (5) 
The coefficients of variation estimated from the inversely estimated con- 
centrations (as above) were 20.5%, 21.0%, t9.8%, 22.9%, and 26.3% for 
actual concentrations of 2, 4, 6, 10, and 20 ng/ml, respectively, and the bias 
values, calculated from the means, were - 2 . 0 % ,  4.3%, 8.2%, 7.0%, and 
3.5%, respectively, for concentrations in the same order. 
The calibration data for each subject in each study were collected on a 
different day; hence the above figures include both intra- and inter-day 
variation. 
P|asma Levels of Prednisolone 
The cross-reactivity of prednisolone, the prednisolone metabolite 2013- 
dihydroprednisolone, and cortisot with the antiserum of W. A. Colburn has 
been previously reported (13). We demonstrated that plasma concentra- 
tions of prednisolone were identical when assayed by the two antisera. 
Hydrocortisone cross-reacts with both antisera. Hence, in order to obtain a 
Table II, Summary of Results of Prednisotone Study No. 2 
Treatment averages 
Parameter U Re St Mc 





0.25 hr 71.7 46.3 50.8 31o2 
0.50 hr 157, 146. 135. 136, 
1.0 h~ 240, 228. 217. 211. 
2.0 hr 205. 206. 209. 200. 
3.0 hr 179. 167, 174. 163. 
4.0 hr 153. 128. 143. 144. 
6.0 hr 90.6 90.6 87.8 89.5 
8.0 hr 53.2 45.4 50.7 49.1 
12.0 hr I7.3 15.6 17.8 17.1 
24.0 Jar 2.35 1.68 3.26 2.00 
Peak plasma level (ng/ml) 257. 238. 238. 232. 
Time of peak plasma 
level (hr) 1.42 1.25 1.13 1.50 
Area 0-12 hr 
[(ng/ml) • hr] 1246. 1129. 1187. 1157. 
Area 0-24 hr 
[(ng/ml) x hr] 1364. 1233. I314. 1271. 
Half-life (hr) 2.55 2.60 2.77 2.62 
NS (0.05 <p  <0.10) 
NS (p >0.25) 
NS (p >0.25) 
NS (p > 0.25) 
NS (p > 0,25) 
NS (0,10 <p  < 0.25) 
NS (p > 0.25) 
NS (p > 0.25) 
NS (p > 0.25) 
NS (0.1 <p  <0.25) 
NS (p > 0.25) 
NS (p > 0.25) 
NS 0,10<p <0.25) 
NS (0.10<p <0.25) 
NS (p > 0.25) 
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more specific assay for prednisolone, it was necessary to suppress adrenal 
function with dexamethasone. 
The average plasma concentrations of prednisolone following the four 
different treatments studied in Prednisolone Study No. 2 are summarized in 
Table II. There were no significant differences among the treatment average 
plasma concentrations at any sampling time. There were no significant 
differences among the treatment averages for peak plasma concentration, 
area 0-12 hr, area 0-24 hr, or the apparent half-life of elimination of 
prednisolone. The coefficients of variation of the averages shown in Table II 
are given in Table III. 
The average plasma concentrations of prednisoione following the oral 
administration of the four treatments studied in Prednisolone Study No. 3 
are summarized in Table IV. There were statistically significant differences 
among the treatment average plasma concentrations at 0.25 and 4 hr, but 
not at all other sampling times. There were also no significant differences 
among the treatment averages for peak plasma concentration, area 0-12 hr, 
area 0-24 hr, or the apparent half-life of prednisolone. Table V gives the 
coefficients of variation of the averages shown in Table IV. 
Another important consideration is the power of the analysis of var- 
iance. If the hypothesis that the means were equal was false, a so-called type 
Table HI. Coefficients of Variation of Treatment Averages Given in Table II 
Coefficients of variation (%) 
for treatments 
Parameter U Re St Mc 
c.v.(O/o) 
from RMS ~ 
of ANOVA b 
Plasma concentration (ng/ml) 
0.25 hr 74.9 80.7 83.3 86.1 67.9 
0.50 hr 42.1 37.9 40.3 50.1 42.5 
1.0 hr 18.9 17.4 19.9 32.6 21.2 
2 .0hr  11.0 15,0 18.2 26.7 15.1 
3.0 hr 12.3 12.9 16.5 25.0 14.4 
4 .0hr  29.1 12.7 19,5 22.4 18.8 
6,0 hr 23.3 14.6 18,7 23.8 18.6 
8.0 hr 33.9 16.4 21,1 27.4 26.5 
12.0 hr 41.6 42.9 33,1 45.7 35.9 
24.0 hr 91.0 124. 87,2 110. 84.5 
Peak plasma level (ng/ml) 10.1 14.1 12.0 22.4 13.9 
Time of peak plasma level (br) 70.3 57.8 38.5 60.3 72.7 
Area 0-12 hr [(ng/mi) • hr] 10.8 8.58 10.8 19.0 10.7 
Area 0-24 hr [(ng/ml) • br] 13.0 9.5 12.1 19.0 11.9 
Half-life (hr) 22.6 14.6 18.4 15.5 13.2 
a RMS = residual mean square. 
bANOVA = analysis of variance for crossover design. 
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Table IV. Summaryof Results of Prednisolone Study No, 3 
Treatment averages 
Parameter R ST O U 





0.25 hr 22.1 86.9 36.9 47,2 0.025 <p < 0,05 
0.50 hr 106. 180. I67. 165.0 NS (0.05 <p <0.1) 
1.0 hr 223. 255. 257. 234.0 NS (p > 0.25) 
2.0 hr 212, 232. 228. 238.0 NS (t9 > 0.25) 
3.0 hr 178, 199. 182. 202.0 NS (p > 0.25) 
4.0hr 125. 158. 138. 154.0 0.025<p <0.05 
6.0hr 71.1 92.2 76,4 83.7 NS (0.05 <p <0,1) 
8.0hr 37.0 45.7 36.5 43.4 NS(p>0.25) 
12.0 hr 10,4 18.2 13.1 12.6 NS (0.1 <p < 0.25) 
24.0 hr 1.62 4.34 4.45 3.30 NS (p > 0.25) 
Peak plasma level (ng/ml) 240.0 262.0 263.0 254.0 NS (p > 0.25) 
Time of peak plasma 
level (hr) 1.42 1.21 1.00 1,33 NS (p > 0.25) 
Area 0-12 hr 
[(ng/ml)x hr] 1052, 1 3 0 7 .  1 1 7 1 ,  1 2 4 2 .  NS(0.05 <p <0,1) 
Area 0-24 hr 
[(ng/ml)x hr] 1124. 1 4 4 2 .  1 2 7 6 .  1337. NS (0.05 <p <0.1) 
Half-life (hr) 2.I2 2.44 2.30 2.26 NS (p >0.25) 
II error ~ error) would occur if the tested hypothesis was accepted when it 
was false. The probability of rejecting the tested hypothesis when it was false 
is called "the power of the test against a specified alternative" and is denoted 
as 1 - ~ .  For example, if 1 --fl = 0.8, then the chances areO.8 out of 1.0 of 
detecting the specified difference in means. Table VI lists values of 1 - f l  
which were calculated, using the coefficients of variation in the last columns 
of Tables III and V, by the method of Dixson and Massey (14) as illustrated 
for crossover studies by Wagner (15). Calculations were made for both a 
20% and a 30% difference in extreme means with c~ = 0.05. As is usual in 
such evaluations of most bioavallability data, the 1 - / / va lues  vary widelyw 
in this case, from <0.3  to >0.99.  The 1-/~ values are >-0.8, the usually 
desired values, for plasma concentrations at 1, 2, 3, 4, and 6 hr, peak plasma 
level, area 0-12 hr, area 0-24 hr, and half-life when the specified difference 
in extreme means is 30%; nine of the values are ---0.8 when the specified 
difference in extreme means is 20%. Our conclusion of bioequivalence 
(below) is principally based on the results of analyses of variance of the areas 
and the peak concentrations, and for these parameters there is excellent 
power usually with the 20% difference and always with the 30% difference. 
Although some readers may disagree with inclusion of Fig. 3 (discussed 
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Table V. Coefficients of Variation of Treatment Averages Given in Table IV 
Coefficients of variation (%) 
for treatments 
Parameter R ST O U 
c.v.(%) 
from RMS ~ 
of ANOVA b 
Plasma concentration (ng/ml) 
0.25 hr 80.2 97.1 86.1 116. 114. 
0.5 hr 43.2 51.4 47.1 48.3 45.6 
1.0 hr 28.7 22.9 18.9 17.2 21.2 
2.0 hr 20.1 18.0 15.4 16.2 15.0 
3.0 hr 26.8 20.2 21.0 20.5 18.3 
4.0 hr 28.1 23.6 19.0 19.1 19.6 
6.0 hr 43.7 33.8 22.0 26.7 25.9 
8.0 hr 65.6 52.2 35.4 40.9 38.0 
12.0 hr 66.7 73.7 44.2 40.9 57.6 
24.0 hr 142. 74.8 104. 153. 124. 
Peak plasma level (ng/ml) 20.1 20.1 16.2 12.2 15.2 
Time of peak plasma level (hr) 47.2 47.2 36.9 46.2 43.9 
Area 0-12 hr [(ng/ml) x hr] 26.5 26.8 18.4 17.6 19.0 
Area 0-24 hr [(ng/ml) • hr] 28.4 30.2 20.5 19.0 29.0 
Half-life (hr) 14.0 25.3 14.5 13.0 17.8 
a RMS = residual mean square. 
bANOVA = analysis of variance for crossover design. 
Table VI. Values of the Power (1- /3)  of the Analyses of Variance Using Coefficients of 




Prednisolone Study No. 2 Prednisolone Study No. 3 
20% 4 30% b 20% ~ 30% b 
Plasma concentration (ng/ml) 
0.25 hr <0.3 <0.3 <0.3 <0.3 
0.50 hr <0.3 0.35 <0.3 <0.3 
1.0 hr 0.50 0.94 0.50 0.92 
2.0 hr 0.86 > 0.99 0.86 > 0.99 
3.0 hr 0.89 0.99 0.65 0.985 
4.0 hr 0.65 0.98 0.62 0.965 
6.0 hr 0.65 0.98 0.38 0.80 
8.0 hr 0.38 0.78 <0.3 0.43 
12.0 hr <0 .3  0.50 <0.3  <0.3  
24.0 hr <0.3  <0.3  <0 .3  <0.3  
Peak plasma level (ng/ml) 0.91 >0.99  0.86 >0.99  
Time of peak plasma level (hr) < 0.3 < 0.3 < 0.3 0.33 
Area 0-12 hr [(ng/ml)x hr] >0.99 >0.99  0.65 0.978 
Area 0-24 hr [(ng/ml) x hr] 0.978 > 0.99 0.50 0.942 
Half-life (hr) 0.94 > 0.99 0.72 0.986 
a Calculated for extreme means differing by 20% and specifically for means of 100, 93.3, 86.7, 
and 80. 
bCaleulated for extreme means differing by 30% and specifically for means of 100, 90, 80, and 
70 using the method of Dixson and Massey (14). 
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Fig. 3. Hatched area, bounded by the two solid lines, 
includes the average prednisolone plasma concen.trations 
following oral administration of 10 ng of prednisolone as 
nine different prednisolone tablets made by eight different 
manufacturers which were studied in Prednisolone Studies 
No. 1, 2, and 3. 
below), since it is a cross-study comparison involving different subjects, the 
authors wished to include it for clinically oriented readers, who, the authors 
believe, would also conclude bioequivalency. 
Figure 3 summarizes the average prednisolone concentrations in all 
three prednisolone studies, where Prednisotone Study No. i was previously 
reported by Sullivan et al. (4). The plot includes data obtained with pred- 
nisolone tablets from nine different tablets made by eight different manufac- 
turers. Ir: light of the statistics reported for each of the three studies, the 
authors conclude that the average prednisotone concentrations are superim- 
posable and that the nine different tablets tested are bioequivalent. The 
authors would like to caution that this conclusion not be extrapolated to all 
marketed prednisolone tablets. 
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